西妥昔单抗、紫杉醇和顺铂新辅助生物化疗序贯西妥昔单抗同步生物放疗治疗高危局部晚期口腔鳞状细胞癌的2期临床试验最终分析
这项2期临床试验纳入47例初治的晚期口腔或口咽部肿瘤患者,采用西妥昔单抗、紫杉醇和顺铂新辅助治疗后继以西妥昔单抗为基础的放疗。最佳总缓解率为70.2%,中位无进展生存期和总生存期分别为10.3个月和15.2个月。新辅助治疗后肿瘤缩小超过50%的患者生存结局更好,22例发生严重不良事件,主要为皮肤并发症。
要点
- 最佳总缓解率为70.2%,包括4例完全缓解和29例部分缓解。
- 中位无进展生存期10.3个月,中位总生存期15.2个月。
- 新辅助治疗后肿瘤缩小超过50%的患者生存结局更好。
核心结论
- 该方案在部分选择患者中有效,PD-L1表达增加提示肿瘤特征改变。
研究设计与样本
- 2期临床试验,纳入47例初治的晚期口腔或口咽部肿瘤患者。
主要发现
- 最佳总缓解率为70.2%,包括4例完全缓解和29例部分缓解。
- 中位无进展生存期和总生存期分别为10.3个月和15.2个月。
- 新辅助治疗后肿瘤缩小超过50%的患者生存结局更好。
- 22例发生严重不良事件,主要为皮肤并发症。
- 16例接受手术的患者中,9例术后PD-L1染色较治疗前活检增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognosis of advanced oral squamous cell carcinoma is poor. We investigated the effect of cetuximab-based sequential therapy as a primary treatment. METHODS: Forty-seven treatment-naive patients with advanced tumors originating from the oral cavity or oropharynx were enrolled. Neoadjuvant cetuximab, paclitaxel, and cisplatin were administered, followed by cetuximab-based radiotherapy. Immunohistochemical staining was applied to study the tissues. RESULTS: The best overall response rate was 70.2%, including 4 patients with a complete response and 29 with a partial response. The median progression-free and overall survival rates were 10.3 and 15.2 months, respectively. Patients with more than 50% tumor reduction with neoadjuvant therapy had better survival outcomes. Twenty-two patients had severe adverse events with mostly dermatological complications. Of the 16 patients who received operations, 9 had increased PD-L1 staining compared to pretreatment biopsy in the post hoc study. CONCLUSION: The regimen was effective in selected patients. Increased PD-L1 suggested altered tumor features.
引用
- Yen CJ, Tsou HH, Hsieh CY, et al. Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: Final analysis of a phase 2 clinical trial. Head Neck. 2019. PMID: 30636183. doi:10.1002/hed.25640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。